122 related articles for article (PubMed ID: 37013774)
21. METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL.
Wu Y; Jin M; Fernandez M; Hart KL; Liao A; Ge X; Fernandes SM; McDonald T; Chen Z; Röth D; Ghoda LY; Marcucci G; Kalkum M; Pillai RK; Danilov AV; Li JJ; Chen J; Brown JR; Rosen ST; Siddiqi T; Wang L
Blood Cancer Discov; 2023 May; 4(3):228-245. PubMed ID: 37067905
[TBL] [Abstract][Full Text] [Related]
22. METTL3-mediated m6A mRNA contributes to the resistance of carbon-ion radiotherapy in non-small-cell lung cancer.
Xu X; Zhang P; Huang Y; Shi W; Mao J; Ma N; Kong L; Guo L; Liu J; Chen J; Lu R
Cancer Sci; 2023 Jan; 114(1):105-114. PubMed ID: 36114749
[TBL] [Abstract][Full Text] [Related]
23. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
24. JNK Signaling Promotes Bladder Cancer Immune Escape by Regulating METTL3-Mediated m6A Modification of PD-L1 mRNA.
Ni Z; Sun P; Zheng J; Wu M; Yang C; Cheng M; Yin M; Cui C; Wang G; Yuan L; Gao Q; Li Y
Cancer Res; 2022 May; 82(9):1789-1802. PubMed ID: 35502544
[TBL] [Abstract][Full Text] [Related]
25. Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
Liu GM; Zeng HD; Zhang CY; Xu JW
Dig Dis Sci; 2021 Apr; 66(4):1110-1126. PubMed ID: 32333311
[TBL] [Abstract][Full Text] [Related]
26. Four m6A RNA Methylation Gene Signatures and Their Prognostic Values in Lung Adenocarcinoma.
Wang Y; Zhao X; Li J; Wang X; Hu W; Zhang X
Technol Cancer Res Treat; 2022; 21():15330338221085373. PubMed ID: 35343834
[No Abstract] [Full Text] [Related]
27. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner.
Wang X; Lu X; Wang P; Chen Q; Xiong L; Tang M; Hong C; Lin X; Shi K; Liang L; Lin J
J Transl Med; 2022 May; 20(1):198. PubMed ID: 35509101
[TBL] [Abstract][Full Text] [Related]
28. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
29. Integrative Analyses of m6A Regulators Identify that METTL3 is Associated with HPV Status and Immunosuppressive Microenvironment in HPV-related Cancers.
Yu R; Wei Y; He C; Zhou P; Yang H; Deng C; Liu R; Wu P; Gao Q; Cao C
Int J Biol Sci; 2022; 18(9):3874-3887. PubMed ID: 35813476
[TBL] [Abstract][Full Text] [Related]
30. m
Shen C; Xuan B; Yan T; Ma Y; Xu P; Tian X; Zhang X; Cao Y; Ma D; Zhu X; Zhang Y; Fang JY; Chen H; Hong J
Mol Cancer; 2020 Apr; 19(1):72. PubMed ID: 32245489
[TBL] [Abstract][Full Text] [Related]
31. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.
Taketo K; Konno M; Asai A; Koseki J; Toratani M; Satoh T; Doki Y; Mori M; Ishii H; Ogawa K
Int J Oncol; 2018 Feb; 52(2):621-629. PubMed ID: 29345285
[TBL] [Abstract][Full Text] [Related]
32. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
[No Abstract] [Full Text] [Related]
33. Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/β-catenin signalling pathway.
Cui X; Wang Z; Li J; Zhu J; Ren Z; Zhang D; Zhao W; Fan Y; Zhang D; Sun R
Cell Prolif; 2020 Mar; 53(3):e12768. PubMed ID: 31967701
[TBL] [Abstract][Full Text] [Related]
34. Upregulation of METTL3 expression and m6A RNA methylation in placental trophoblasts in preeclampsia.
Gu Y; Chu X; Morgan JA; Lewis DF; Wang Y
Placenta; 2021 Jan; 103():43-49. PubMed ID: 33070036
[TBL] [Abstract][Full Text] [Related]
35. METTL3 promotes prostate cancer progression by regulating miR-182 maturation in m6A-dependent manner.
Wang D; Wang X; Huang B; Zhao Y; Tu W; Jin X; Shao Y; Zhu Y; Lu G
Andrologia; 2022 Aug; 54(7):1581-1591. PubMed ID: 35413135
[TBL] [Abstract][Full Text] [Related]
36. Changes of N6-methyladenosine modulators promote breast cancer progression.
Wu L; Wu D; Ning J; Liu W; Zhang D
BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
[TBL] [Abstract][Full Text] [Related]
37. m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Xu J; Chen Q; Tian K; Liang R; Chen T; Gong A; Mathy NW; Yu T; Chen X
Oncol Rep; 2020 Sep; 44(3):973-986. PubMed ID: 32705223
[TBL] [Abstract][Full Text] [Related]
38. Reduced N6-Methyladenosine Mediated by METTL3 Acetylation Promotes MTF1 Expression and Hepatocellular Carcinoma Cell Growth.
Yang Y; Qian Cai Q; Sheng Fu L; Wei Dong Y; Fan F; Zhong Wu X
Chem Biodivers; 2022 Nov; 19(11):e202200333. PubMed ID: 36149370
[TBL] [Abstract][Full Text] [Related]
39. METTL3‑mediated m6A modification of Bcl‑2 mRNA promotes non‑small cell lung cancer progression.
Zhang Y; Liu S; Zhao T; Dang C
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34132367
[TBL] [Abstract][Full Text] [Related]
40. METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way.
Dou X; Wang Z; Lu W; Miao L; Zhao Y
BMC Pulm Med; 2022 Aug; 22(1):324. PubMed ID: 36008805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
